Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Negative symptoms of schizophrenia: new developments and unanswered research questions
Silvana Galderisi, Armida Mucci, Robert W. Buchanan, et al.
The Lancet Psychiatry (2018) Vol. 5, Iss. 8, pp. 664-677
Closed Access | Times Cited: 441

Showing 1-25 of 441 citing articles:

Schizophrenia—An Overview
Robert A. McCutcheon, Tiago Reis Marques, Oliver Howes
JAMA Psychiatry (2019) Vol. 77, Iss. 2, pp. 201-201
Closed Access | Times Cited: 1002
<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>
Christoph U. Correll, Nina R. Schooler
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 519-534
Open Access | Times Cited: 559
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 513
The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders
Katarzyna Socała, Urszula Doboszewska, Aleksandra Szopa, et al.
Pharmacological Research (2021) Vol. 172, pp. 105840-105840
Open Access | Times Cited: 508
Structure and neural mechanisms of catatonia
Sebastian Walther, Katharina Stegmayer, Jo Ellen Wilson, et al.
The Lancet Psychiatry (2019) Vol. 6, Iss. 7, pp. 610-619
Open Access | Times Cited: 262
The clinical characterization of the patient with primary psychosis aimed at personalization of management
Mario Maj, Jim van Os, Marc D. Binder, et al.
World Psychiatry (2021) Vol. 20, Iss. 1, pp. 4-33
Open Access | Times Cited: 226
EPA guidance on assessment of negative symptoms in schizophrenia
Silvana Galderisi, Armida Mucci, Sonia Dollfus, et al.
European Psychiatry (2021) Vol. 64, Iss. 1
Open Access | Times Cited: 176
EPA guidance on treatment of negative symptoms in schizophrenia
Silvana Galderisi, Stefan Kaiser, István Bitter, et al.
European Psychiatry (2021) Vol. 64, Iss. 1
Open Access | Times Cited: 136
Primary and Secondary Negative Symptoms in Schizophrenia
Sergey Mosolov, Polina A. Yaltonskaya
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 72
Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium
Dick Schijven, Merel C. Postema, Masaki Fukunaga, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 14
Open Access | Times Cited: 52
Neuroimaging biomarkers define neurophysiological subtypes with distinct trajectories in schizophrenia
Yuchao Jiang, Jijun Wang, Enpeng Zhou, et al.
Nature Mental Health (2023) Vol. 1, Iss. 3, pp. 186-199
Closed Access | Times Cited: 48
Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments
Stephen R. Marder, Daniel Umbricht
Schizophrenia Research (2023) Vol. 258, pp. 71-77
Open Access | Times Cited: 44
Deep Learning Models for Diagnosis of Schizophrenia Using EEG Signals: Emerging Trends, Challenges, and Prospects
Rakesh Ranjan, Bikash Chandra Sahana, Ashish Kumar Bhandari
Archives of Computational Methods in Engineering (2024) Vol. 31, Iss. 4, pp. 2345-2384
Closed Access | Times Cited: 19
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
William P. Horan, Steven D. Targum, Amy Claxton, et al.
Schizophrenia Research (2024) Vol. 274, pp. 57-65
Open Access | Times Cited: 18
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 2
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
Wolfgang Fleischhacker, Silvana Galderisi, I. Laszlovszky, et al.
European Psychiatry (2019) Vol. 58, pp. 1-9
Open Access | Times Cited: 104
Pathophysiology of negative symptom dimensions of schizophrenia – Current developments and implications for treatment
Indrit Bègue, Stefan Kaiser, Matthias Kirschner
Neuroscience & Biobehavioral Reviews (2020) Vol. 116, pp. 74-88
Open Access | Times Cited: 93
Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits
David R. Goldsmith, Mark Hyman Rapaport
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 85
EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review
Andrea Perrottelli, Giulia Maria Giordano, Francesco Brando, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 83
Targeting muscarinic receptors to treat schizophrenia
Daniel J. Foster, Zoey Bryant, P. Jeffrey Conn
Behavioural Brain Research (2021) Vol. 405, pp. 113201-113201
Open Access | Times Cited: 69
Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
Gregory P. Strauss, Lisa A. Bartolomeo, Philip D. Harvey
Schizophrenia (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 67
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe
Dragana Bugarski‐Kirola, Celso Arango, Maurizio Fava, et al.
The Lancet Psychiatry (2021) Vol. 9, Iss. 1, pp. 46-58
Closed Access | Times Cited: 60
Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends
Michel Sabé, Chaomei Chen, Natacha Perez, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 144, pp. 104979-104979
Open Access | Times Cited: 54
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis
Donal O’Keeffe, Anthony Kinsella, John L. Waddington, et al.
American Journal of Psychiatry (2022) Vol. 179, Iss. 4, pp. 288-297
Closed Access | Times Cited: 48
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Michael Davidson, Jay Saoud, Corinne Staner, et al.
Schizophrenia Bulletin (2022) Vol. 48, Iss. 3, pp. 609-619
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top